Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-08-15
1998-10-06
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 551, A61K 3170
Patent
active
058176420
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
This invention relates to the treatment of arterial disease and pharmaceutical compositions suitable for such use. Particularly the invention relates to the clearing of atherosclerosis.
BACKGROUND OF THE INVENTION
Atherosclerosis is prevalent in the North American population believed to be caused in part by a diet rich in cholesterol. Over the years, deposits of yellowing plaques (atheromos) containing for example cholesterol, other lipoid material, lipophages and/or other substances build up on the inner wall of the arteries (for example within the intima of large and medium-sized arteries) of a person causing the arteries to narrow inhibiting the free flow of blood. That person thus increases his/her risk of becoming a heart attack and/or stroke victim.
Balloon angioplasty is a widely accepted method of opening blockages in the coronary arteries. However in some patients after successful treatment by balloon angioplasty, arterial restenosis occurs. This time however the narrowing of the inner diameter (ID) of the artery is caused by growth (proliferation) of endothelial cells in the areas of irritation caused by the balloon angioplasty. Thus reblockage occurs not by cholesterol build-up but by build up of endothelial cells on the inner wall of the artery reducing the inner diameter (ID) of the artery leading to an infarct. This narrowing of the inner diameter (ID) of tubular walls or proliferation of cells is not however restricted or limited to the coronary arteries. It can also occur post operatively causing restenosis in for example peripheral vascular systems.
It is therefore an object of this invention to provide a new method of clearing atherosclerosis.
It is a further object of the invention to provide a new method of clearing the arteries of atheromos containing for example cholesterol, other lipoid material, lipophages and/or other substances.
It is a further object of this invention to provide pharmaceutical compositions suitable for use in such methods of treatment.
It is still a further object of this invention to provide dosage amounts of the pharmaceutical composition suitable for use in such methods of treatment.
Further and other objects of the invention will be realized by those skilled in the art from the following.
In accordance with the invention, Applicants have provided a new method and treatment of clearing atherosclerosis in which deposits of plaques (atheromos) containing cholesterol, other lipoid material, lipophages and other substances have built up within the arterial walls of a patient for example within the intima of large and medium-sized arteries. The method of treatment comprises administering for example, intravenously to a patient, at least one dosage amount of a pharmaceutical composition formulated according to embodiments of the invention. While the number and timing of administration of each dosage amount varies from patient to patient, dosage amounts administered over a number of weeks (for example 2-12 weeks) at intervals of for example two-three days from one administration to the next administration are suitable. One patient was given 45 treatments over a 5-6 week period in equal intervals. Another patient required only two treatments. Still another patient received dosage amounts intravenously over a period of 12 weeks at two dosage amounts per week. The dosage amounts comprise an effective non-toxic amount of each of a chelating agent, for example and preferably EDTA (common name for ethylenediaminetetraacetic acid), a non-steroidal anti-inflammatory drug (NSAID) (for example diclofenac, tromethamine salt of ketoralac (sold under the trade mark Toradol), indomethacin, piroxicam, ibuprofen), an anti-oxidant (for example and preferably vitamin C) and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof (for example the sodium salt), homologues, analogues, derivatives, esters, complexes, fragments and subunits. The form of hyaluronic acid is preferably sodium hyaluronate having a molecular weight of less than about 750,0
REFERENCES:
Falk, R. Round Table Ser. R. Soc. Med., No. 33, 1994 pp. 2-10.
H. Beyer et al., 'Lehrbueh der Organischer Chemie' 1976, S. Hirzel Verlag, Stuttgart, FRG, p. 366.
J.E.F. Reynolds 'Martindal, The Extra Pharmacopoeia' 1993.
Asculai Samuel Simon
Falk Rudolf Edgar
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Peselev Elli
Sarkis Marcelo K.
LandOfFree
Clearing of atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clearing of atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clearing of atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77189